Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Theratechnologies Inc T.TH

Alternate Symbol(s):  THTX

Theratechnologies Inc. is a Canada-based clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapies addressing unmet medical needs. It markets prescription products for people with human immunodeficiency viruses (HIV) in the United States. The Company's research pipeline focuses on specialized therapies addressing unmet medical needs in HIV, nonalcoholic steatohepatitis (NASH) and oncology. Its medicines include Trogarzo and EGRIFTA SV (tesamorelin for injection). Trogarzo (ibalizumab-uiyk) injection is a long-acting monoclonal antibody which binds to domain 2 of the CD4 T cell receptors. It blocks viral entry into host cells while preserving normal immunologic function. The Company is also investigating an intramuscular method of administration of Trogarzo. EGRIFTA SV (tesamorelin for injection) is approved in the United States for the reduction of excess abdominal fat in people with HIV who have lipodystrophy.


TSX:TH - Post by User

Comment by palinc2000on Mar 13, 2023 4:56pm
54 Views
Post# 35335999

RE:Cash strapped company

RE:Cash strapped company

If you add the self inflicted wound of opting for a Convert  5 yesrs ago instead of a shsre issue (55 million$) plus the outlays to acquire Katana plus the RD since (15 million$ my estimate)  that makes a difference of 70 millions$ not including the opportunity cost of being limited in options to accelerate sales ( in licensing) etc
 


palinc2000 wrote: How did THTX get there?Self inflicted wounds
1-Opting to issue a Convert 5 years ago instead of issuing stock

If they issued stock instead of debt Marathon would not be in the picture

2-Buying Katana and going into a wild goose chase with insufficient know how and insufficient cash 

3-Flawed strategy for sales of Egrifta when bough back from Serono and flawed launch of Trogarzo from the very start 

ALL OF THE ABOVE WAS UNDER THE LEADERSHIP  OF THE FORMER CEO LUC TANGUAY 


Paul Levesque is nor perfect but had he not grown sales THTX would be moribond 

My biggest peeve against Paul is that he did not see fit to replace the CFO days after he joiined .....I wrote at the time new broom sweeps clean    unfortunately he did not listen....,,



 

<< Previous
Bullboard Posts
Next >>